Browsing Tag
Bristol Myers Squibb
54 posts
Oxford Biomedica (LSE: OXB) plunges 15% as 2026 revenue guidance falls
Oxford Biomedica cut 2026 revenue guidance by £40m at midpoint. September results must show whether OXB’s setback is timing or something deeper.
Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up
Braveheart Bio is seeking up to $318.8 million in its Nasdaq IPO, but investors must decide whether its cardiac myosin inhibitor can compete in an increasingly crowded hypertrophic cardiomyopathy market.
Cytokinetics secures UK approval and NHS access for aficamten in obstructive HCM
UK approval and NICE reimbursement give aficamten access to 6,600 patients as Cytokinetics expands its global HCM commercial launch.
![Ratio Therapeutics’ $70 million Series C financing will support the ATLAS trial of [Ac-225]RTX-2358, expand its targeted radiotherapeutics pipeline and strengthen radiopharmaceutical manufacturing capacity. Representative image.](https://business-news-today.com/wp-content/uploads/2026/07/Ratio-Therapeutics-raises-70-million-to-advance-ATLAS-trial-and-radiopharmaceutical-manufacturing-380x280.png)
Can Ratio Therapeutics turn a $70m funding round into a scalable cancer-treatment platform?
Ratio Therapeutics’ Series C financing gives the Boston oncology company additional capital to advance [Ac-225]RTX-2358, bring another radioligand therapy into clinical development and expand the manufacturing network needed to support a broader cancer pipeline.
Takeda’s zasocitinib shows high clearance rates at difficult psoriasis sites
Scalp and palmoplantar clearance rates approached 70% to 77%, but regulatory review, safety labelling and market access will determine the commercial impact.
Ipsen to buy Kartos Therapeutics for up to $1.75bn as IPN nears 52-week high
Ipsen is buying Kartos for up to $1.75 billion. Read how navtemadlin could reshape its oncology pipeline, earnings outlook and IPN valuation after the deal.
Kardigan’s IPO demand looks strong, but the real test for KARD arrives in 2027
Kardigan raises $400 million in an upsized Nasdaq IPO to fund three cardiovascular trials. Discover the catalysts, cash runway and risks for KARD investors.
Replimune (REPL) soars 86% as WSJ says White House intervention reopens RP1 review
Replimune jumped nearly 86% after the WSJ reported White House officials pushed the FDA to reconsider twice-rejected RP1. A reopened path, and a binary bet on approval.
Bristol Myers Squibb myeloma drug doubles progression-free survival in pivotal SUCCESSOR-2 trial
Bristol Myers Squibb's mezigdomide doubled myeloma progression-free survival to 18 months and cut progression or death risk 52% in Phase 3, key to its patent-cliff plan.
JW Therapeutics says China pharma deals remain insulated from Beijing’s sensitive technology scrutiny
JW Therapeutics says China pharma deals remain open despite Beijing tech scrutiny. See why biotech licensing still matters.